Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 354Lymphoma 306Lymphoma, Follicular 268Lymphoma, Non-Hodgkin 170Leukemia 138Hodgkin Disease 135Multiple Myeloma 130Leukemia, Lymphocytic, Chronic, B-Cell 110Lymphoma, Large B-Cell, Diffuse 108Leukemia, Myeloid, Acute 98Neoplasms 83Lymphoma, Mantle-Cell 70Burkitt Lymphoma 70Myelodysplastic Syndromes 64Breast Neoplasms 62Lymphoma, T-Cell, Cutaneous 60Lymphoma, B-Cell, Marginal Zone 59Myeloproliferative Disorders 50Mycosis Fungoides 50Motor Activity 49Lymphoma, Large-Cell, Immunoblastic 47Sezary Syndrome 44Neoplasms, Plasma Cell 42Hematologic Neoplasms 41Dementia 41Primary Myelofibrosis 39Leukemia, Myeloid, Chronic-Phase 38Leukemia, Myeloid, Accelerated Phase 38Congenital Abnormalities 38Recurrence 37

Interventions

Daptomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Fasciitis, Necrotizing × Lymphoid × Clear all
NCT00261807 2022-01-27

Daptomycin for the Treatment of Severe Necrotizing Soft-Tissue Infections

University of Maryland, Baltimore

Phase NA Completed
25 enrolled 7 charts
Lymphoid

Infections, Lymphoma, Follicular, Soft Tissue Infections, Fournier Gangrene, Fasciitis, Necrotizing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡